Status:
COMPLETED
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Lead Sponsor:
Taichung Veterans General Hospital
Conditions:
Schizophrenia; Psychosis
Metabolic Syndrome
Eligibility:
All Genders
20-65 years
Phase:
PHASE4
Brief Summary
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related fact...
Detailed Description
Objectives The effects of adjunctive Fute (Flupentixol) with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) on the metabolic profiles of patients and clinical efficacy of treatment in schi...
Eligibility Criteria
Inclusion
- Patients who suffer from schizophrenia are over 20 years old and are using MARTAs antipsychotics.
Exclusion
- \>65y aged Patients.
- \>Other non-schizophrenia disease.
Key Trial Info
Start Date :
December 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04898270
Start Date
December 19 2019
End Date
April 20 2021
Last Update
May 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taichung Veterans General Hospital
Taichung, Taiwan, 40705